CIBC Private Wealth Group
KALV

CIBC Private Wealth Group’s KalVista Pharmaceuticals KALV Stock Holding History

CIBC Private Wealth Group’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-160
Closed -$1.95K – 3481
2025
Q3 		$1.95K Hold
160
– – ﹤0.01% 2732
2025
Q2 		$1.81K Hold
160
– – ﹤0.01% 2661
2025
Q1 		$1.65K Buy
+160
New +$1.63K ﹤0.01% 2727

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

CIBC Private Wealth Group's KALV Position: Q4 2025 in Review

CIBC Private Wealth Group sold out of KalVista Pharmaceuticals (KALV) in Q4 2025, closing a stake of 160 shares — an estimated $1.95K sold.

CIBC Private Wealth Group first reported a position in KALV in Q1 2025 and held it in 3 quarters. The position peaked at $1.95K in Q3 2025. 161 funds tracked by Wall St. Rank hold KALV as of Q4 2025.

  • CIBC Private Wealth Group reported no remaining KalVista Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • CIBC Private Wealth Group sold 160 KalVista Pharmaceuticals shares in Q4 2025, an estimated $1.95K.
  • CIBC Private Wealth Group first reported a position in KalVista Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • CIBC Private Wealth Group's KalVista Pharmaceuticals position peaked at $1.95K in Q3 2025.
  • 161 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.